Percutaneous Coronary Intervention

Long and Mid-Term Efficacy and Safety of Clopidogrel versus Ticagrelor following Elective Percutaneous Coronary Intervention

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202606569630048

Enrollment

100

Registered

2026-06-26

Start date

2020-03-03

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiology

Interventions

Treatment with aspirin and clopidogrel post Percutaneous coronary angiography

Treatment with aspirin and ticagrelor post Percutaneous coronary angiography

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with stable coronary artery disease undergoing elective PCI. Both genders were included. Age between 18 and 80 years.

Exclusion criteria

Exclusion criteria: Patients with acute coronary disease. Patients with End stage renal disease. Patients with End stage liver disease. Haemodynamically unstable patients. Patients with history of previous intracerebral bleed at any time. Patients with history of gastrointestinal bleed within 6 months. Patient with major surgery within 30 days. Prior coronary intervention (PCI or CABG).

Design outcomes

Primary

Measure	Time frame
major adverse cardiac events (MACE,including cardiac death, MI, and repeat target-vessel revascularization, Major bleeding incident	—

Secondary

Measure	Time frame
heart failure and minor bleeding event	—

Countries

Egypt

Contacts

Public ContactMohammed Abdel Salam

Professor of Cardiovascular Medicine

dr.salah@live.com+201001835458

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026